Cerebrovascular Events in Pediatric Inflammatory Bowel Disease: A Review of Published Cases

Pejman Rohani, Nazanin Taraghikhah, Mohammad Mehdi Nasehi, Hosein Alimadadi, and Hamid Assadzadeh Aghdaei

Pediatric Gastroenterology and Hepatology Research Center, Children’s Medical Center, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran
Research Institute for Gastroenterology and Liver Disease, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Pediatric Neurology Research Center, Shahid Beheshti University of Medical Sciences, Research Institute for Children Health, Tehran, Iran

ABSTRACT

Pediatric inflammatory bowel disease (PIBD) is a multisystem disorder characterized by intestinal and extraintestinal manifestations and complications. Cerebrovascular events (CVE) are rare extraintestinal complications in patients with PIBD. Statistics show that 3.3% patients with PIBD and 1.3–6.4% adult patients with inflammatory bowel disease (IBD) experience CVE during the course of the disease. Therefore, this study aimed to review the records of children with IBD who developed CVE during the course of the disease. We retrospectively reviewed 62 cases of PIBD complicated by CVE. The mean patient age at the time of thrombotic events was 12.48±4.13 years. The incidence of ulcerative colitis was significantly higher than that of Crohn’s disease (43 [70.5%] vs. 13 [21.3%] patients). Most patients (87.93%) were in the active phase of IBD at the time of CVE. The mean time interval between the onset of IBD and CVE was 20.84 weeks. Overall, 11 (26.83%) patients showed neurological symptoms of CVE at disease onset. The most frequent symptom on admission was persistent and severe headaches (67.85%). The most common site of cerebral venous thrombosis was the transverse sinuses (n=23, 53.48%). The right middle cerebral artery (n=3, 33.34%) was the predominant site of cerebral arterial infarction. Overall, 41 (69.49%) patients who were mostly administered unfractionated heparin or low-molecular-weight heparin (56.09%) recovered completely. Patients with IBD are at a risk of thromboembolism. CVE may be the most common type of thromboembolism. Based on these findings, the most common risk factor for CVE is IBD flares. In patients with CVE, anticoagulant therapy with heparin, followed by warfarin, is necessary.

Keywords: Pediatrics; Inflammatory bowel diseases; Cerebrovascular disorders; Cerebral arterial diseases; Brain infarction

BACKGROUND

Pediatric inflammatory bowel disease (PIBD) is a multisystem disorder characterized by various intestinal and extraintestinal manifestations and complications. With the increasing prevalence of PIBD worldwide, new, rare manifestations and complications have been
Conflict of Interest
The authors have no financial conflicts of interest.

Cerebrovascular events (CVE) are rare extraintestinal complications associated with PIBD. These events include cerebral venous thrombosis (CVT) as an occlusion of the intracranial venous structure (superior sagittal sinus, cortical veins, internal cerebral veins, straight sinus, and some parts of jugular veins) by a clot and cerebral arterial infarction (CAI) as a thromboembolic occlusion of a cerebral artery.

Statistics show that 3.3% patients with PIBD and 1.3–6.4% adult patients experience CVE during the course of the disease [1,2]. However, the precise mechanism of thrombotic events in patients with IBD is unknown. Generally, the risk of CVE is correlated with relapse or disease activity [1,3]. Therefore, in this study, we aimed to review the demographic data, clinical manifestations, risk factors, and sites of CVE in patients with PIBD and investigate the effects of anticoagulant agents on the outcomes of children with IBD who developed CVE during the course of the disease.

MATERIALS AND METHODS
Articles on PIBD complicated by CVE were reviewed retrospectively. A search was conducted in the PubMed, Medline, and Google Scholar using a combination of the following keywords: “cerebral venous thrombosis,” “cerebral arterial infarction,” “cerebral vascular event,” “pediatric inflammatory bowel disease,” “ulcerative colitis” (UC), and “Crohn's disease” (CD). Additionally, the references of the extracted articles were screened. Only articles published in English were included in this review. Information related to the case reports on patients with PIBD complicated by CVE is summarized in Tables 1 [4-41] and 2 [2,4,19,29,42-49].

RESULTS
Demographic data
The mean patient age at the time of the thrombotic event was 12.48±4.13 years. The youngest patient was a 1-year-old female patient with UC. Overall, 32 (50.61%) patients were female. Among patients with PIBD, UC was much more common than CD (43 [70.5%] vs. 13 [21.3%] patients). Most patients (87.93%) were in the active phase of IBD at the time of CVE. The proportions of patients with active UC and CD were almost equal (86.04% and 76.92%, respectively). The mean time interval between the onset of IBD and CVE was 20.84 weeks. Overall, 11 (26.83%) patients showed neurological symptoms of CVE at disease onset. The demographics of patients are presented in Table 3.

Clinical manifestations
The clinical manifestations of 56 (UC=43 and CD=13) of 62 patients were documented. The most frequent symptom on admission was persistent and severe headaches (67.85%). The incidence of headaches was similar in female and male patients, and 25 of 38 patients with headaches had UC (65.78%). Further, 41.07% children developed seizures before admission; among them, 56.52% children were female and 73.91% had UC. In addition, vomiting was reported in 14.28% patients. Moreover, sensory and motor neuropathies were detected in 50% patients. Compared to male patients and patients with CD, the rate of sensory and motor neuropathies in both women and UC patients is 61.53%. Altered levels of consciousness in different forms, such as somnolence, confusion, stupor, or coma, were
### Table 1. Case reports of patients with pediatric inflammatory bowel disease complicated by cerebral venous thrombosis (CVT)

| Case report | Age (y)/Sex | IBD subtype | Time interval between IBD and CVT | Anticoagulant therapy/Outcome | Symptoms | Risk factor | Location of CVT (vessels or brain region) |
|-------------|-------------|-------------|----------------------------------|-------------------------------|----------|------------|------------------------------------------|
| Al-Malik and Green [5] | 14/M | CD | 2 y | No+/No sequel | Headache, seizure | Disease flare, thrombocytosis, surgery, dehydration | Multiple areas of infarction in the occipital lobes, both frontal lobes, and both parietal lobes |
| Al Tahan et al. [8] | 14/F | UC | 6 mo | Heparin, warfarin/No sequel | Headache, seizure | Disease flare, pro-S deficiency | Hemorrhagic infarctions in the left frontal and parietal lobes, widespread thrombosis in the superior sagittal sinus |
| Mahmoud Reza et al. [7] | 11/M | UC | 3 mo | Heparin, warfarin/No sequel | Headache, orbital pain, photophobia, somnolence, transient blurred vision, vomiting | Disease flare | Superior sagittal sinus |
| Barclay et al. [4] | 13/M | UC | 2 wk | Aspirin/Mild hemiplegia | Headache, ataxia, right-sided hemiplegia | Thrombocytosis, history DVT in family | Thalamic and lesion in the left hemisphere involving the motor cortex or radiating fibers |
| Barclay et al. [4] | 11/F | IBD/U | 9 mo | No/Mild hemiplegia | Headache, stupor, right-sided hemiplegia | None | Thalamic/Basal ganglia |
| Barclay et al. [4] | 14/M | CD | 1 y | LMWH/No sequel | Headache | Thrombocytosis, disease flare | Transverse venous thrombosis |
| Rabeh et al. [8] | Unknown | Unknown | Unknown | Unknown | Unknown | Unknown | Undetermined |
| Ben Sassi et al. [9] | 15/F | UC | Unknown | Heparin, warfarin/No sequel | Headache, vomiting, seizure | Thrombocytosis | Lateral sinus |
| Bridger et al. [10] | 14/F | UC | 1 y | Death | Unknown | Disease flare | Widespread venous thrombosis |
| Cogniat et al. [11] | 18/M | UC | 5 y | LMWH, heparin/No sequel | Headache | None | Lateral sinus |
| Conners et al. [12] | 17/F | UC | Unknown | LMWH/No sequel | Headache, confusion, seizure | Disease flare | Superior sagittal sinus, transverse sinus, sigmoid sinus |
| Calderon et al. [13] | 10/F | UC | Unknown | No/Death | Drowsiness, dizziness, right facial droop, right-sided headache | Disease flare | Caudate nucleus, left putamen, left thalamic nucleus |
| DeFilippis et al. [14] | 15/F | CD | 5 y | IV heparin/No sequel | Headache | None | Superior sagittal sinus, transverse sinus, cortical vein |
| DeFilippis et al. [14] | 11/F | UC | 3 y | IV heparin/No sequel | Headache | None | Superior sagittal sinus, transverse sinus, cortical vein |
| DeFilippis et al. [14] | 10/M | UC | 3 y | IV heparin/Coma, death | Headache | None | Superior sagittal sinus, transverse sinus, cortical vein |
| DeFilippis et al. [14] | 12/M | UC | 4 y | Heparin/No sequel | Headache | None | Superior sagittal sinus, transverse sinus, cortical vein |
| Diakou et al. [15] | 17/M | UC | 1.5 y | IV heparin/No sequel | Headache | Protein S deficiency, disease flare | Transverse sinus, sigmoid sinus |
| Houissa et al. [16] | 16/F | UC | 4 y | Heparin/No sequel | Headache, confusion | Disease flare | Undetermined |
| Jibaly and Kaddouarah [7] | 11/F | UC | At disease onset | Heparin/No sequel | Headache | Disease flare | Transverse, sigmoid sinuses, jugular vein |
| Kao et al. [18] | 7/F | UC | Unknown | No/Mild motor deficit | Headache, aphasia | Positive antiphospholipid antibody | Transverse sinus, sigmoid sinus |
| Kao et al. [18] | 13/F | UC | Unknown | Heparin/No sequel | Seizure | Elevated homocysteine | Superior sagittal sinus, transverse sinus, sigmoid sinus |
| Kao et al. [18] | 14/F | UC | Unknown | Heparin/No sequel | Hemiparesis | None | Sigmoid sinus, cortical veins |
| Kalbag et al. [19] | 8/M | UC | Unknown | None | Unknown | Unknown | Undetermined |
| Keene et al. [20] | 5/M | UC | At disease onset | LMWH/Hemiparesis, dysartria | Seizure, confusion, hemiparesis, dysartria | Disease flare, thrombocytosis | Basal ganglia/thalamus and parietal white matter |
| Keene et al. [20] | 12/M | UC | At disease onset | None/No sequel | Bilateral retro-orbital pain | Disease flare, thrombocytosis | Superior sagittal sinus |
| Kim et al. [21] | 17/M | CD | 1 y | Heparin/Mild hemiparesis | Right-side weakness, hypesthesia | None | Superior sagittal sinus, cortical vein |
| Kupfer and Rubin [22] | 16/M | CD | 4 y | IV heparin/No sequel | Headache | Antiphospholipid antibodies | Superior sagittal sinus, transverse sinus |
| Kupfer and Rubin [22] | 9/M | UC | At disease onset | Heparin/No sequel | Headache, left ptosis, bilateral papilledema | Disease flare, thrombocytosis | Transverse sinus, sigmoid sinus |
| Liu et al. [24] | 12/F | UC | At disease onset | LMWH/None | Headache, left-sided hemiparesis and numbness, accompanied by intermittent convulsion | None | Superior sagittal sinus, transverse sinus, sigmoid sinus |
| Macri et al. [25] | 17/F | UC | Unknown | Heparin/No sequel | Headache, mixed aphasia, hemiparesis, seizure | Antithrombin III deficiency, OCP | Superior sagittal sinus, cortical vein |

(continued to the next page)
observed in 16% patients. Ophthalmological manifestations were noted in 21% patients, and blurred vision was the most common manifestation. The clinical manifestations are summarized in Table 4.

**Table 4.** Cerebrovascular Events in Pediatric Inflammatory Bowel Disease: A Review of Published Cases

| Case report | Age (y)/Sex | IBD subtype | Time interval between IBD and CVT | Anticoagulant therapy/Outcome | Symptoms | Risk factor | Location of CVT (vessels or brain region) |
|-------------|-------------|-------------|----------------------------------|------------------------------|----------|------------|----------------------------------------|
| Markowitz et al. [26] | 14/M | UC | 9 mo | Aspirin/No sequel | Headaches, hemiparesis | Disease flare, thrombocytosis | Lateral sinus, sigmoid sinus |
| Martín-Masot et al. [27] | 5/- | UC | 2 y | IV heparin/No sequel | Headache, seizure, monoparesis | Indwelling catheters, MTHFR mutations, disease flare | Transverse sinus |
| Marušić et al. [28] | 13/M | UC | 2 y | Heparin/No sequel | Headache | Disease flare | Superior sagittal sinus, transverse sinus, sigmoid sinus |
| Mayeux and Fahn [29] | 12/F | UC | Unknown | No/Slow recovery | Left focal motor seizure, left hemiparesis, left central facial weakness | Disease flare | Undetermined |
| Patterson et al. [30] | 11/M | UC | Unknown | No/Mild sequel | Unknown | Disease flare | Undetermined |
| Philips et al. [31] | 14/F | IBD/U | Unknown | Local urokinase/No sequel | Neurological deficit | None | Superior sagittal sinus |
| Prasad et al. [32] | 5/F | CD | Unknown | Venous sinus angioplasty and local tPA/No sequel | Headache, expressive aphasia and anoma right homonymous hemiplegia, seizure | Disease flare | Transverse sinus, sigmoid sinus |
| Rivera-Suazo et al. [33] | 3/M | IBD/U | At disease onset | LMWH/No sequel | Seizure | Disease flare | Superior sagittal sinus |
| Robison et al. [34] | 10/M | UC | 3 y | Heparin/No sequel | Headache, vomiting | Factor V Leiden | Transverse sinus, sigmoid sinus |
| Rohani et al. [35] | 19/M | UC | 1 y | Heparin/No sequel | Headache, confusion, aphasia, seizure, right hemiparesis | Disease flare | Left lateral sinus |
| Rosen et al. [36] | 7/M | CD | Unknown | Heparin/No sequel | Headache, vomiting, blur vision | Thrombocytosis, MTHFR mutation heterozygous, prothrombin mutation homozygous | Superior sagittal sinus, transverse sinus, sigmoid sinus |
| Rousseau et al. [37] | 18/M | UC | Unknown | Anticonvulsant | Unknown | Unknown | Superior sagittal sinus |
| Selvtop et al. [38] | 10/F | CD | 5 y | Antibiotic/No sequel | Headache, vomiting, neck pain, stiffness, photophobia, phonophobia, blur vision | Infection | Transverse, sigmoid, cavernous sinuses, internal jugular vein |
| Shahid [39] | 15/M | UC | 3 y | LMWH/No sequel | Headache | Disease flare | Superior sagittal sinus, transverse sinus, internal jugular vein |
| Standridge and de los Reyes [2] | 16/F | CD | 5 mo | Heparin/No sequel | Headache, vomiting, syncope | Prothrombin G20210A mutation, disease flare | Superior sagittal, transverse, sigmoid sinus |
| Standridge and de los Reyes [2] | 18/F | CD | 6 y | LMWH/No sequel | Headache, facial paresthesia | Disease flare, thrombocytosis | Transverse sinus, sigmoid sinus |
| Standridge and de los Reyes [2] | 12/F | CD | At disease onset | Aspirin/No sequel | Nausea, vomiting, headache, difficulty walking, left hemiparesis, complex partial seizure with generalization | Thrombocytosis | Cortical vein |
| Thorsteinsson et al. [40] | 18/M | UC | 5.5 y | Heparin/No sequel | Headache, vomiting | Infection | Transverse sinus |
| Zitomersky et al. [41] | 8/F | UC | Unknown | LMWH/No sequel | Unknown | Disease flare, PT20210A | Undetermined |
| Zitomersky et al. [41] | 15/F | UC | Unknown | LMWH/No sequel | Unknown | Disease flare | Undetermined |

IBD: inflammatory bowel disease, CD: Crohn’s disease, UC: ulcerative colitis, IBD/U: inflammatory bowel disease unclassified, LMWH: low-molecular-weight heparin, MTHFR: methylenetetrahydrofolate reductase, DVT: deep vein thrombosis, IV: intravenous, OCP: oral contraceptive pill, tPA: tissue plasminogen activator.

*aNo refers to no administration of anticoagulants.*
# Table 2. Case reports of patients with pediatric inflammatory bowel disease complicated by cerebral arterial infarction (CAI)

| Case report | Age (y)/Sex | IBD subtype | Time interval between IBD and CAI | Anticoagulant therapy/Outcome | Symptoms | Risk factor | Location of CAI (vessels or brain region) |
|-------------|-------------|-------------|----------------------------------|------------------------------|----------|------------|------------------------------------------|
| Barclay et al. [4] | 7/F CD | 1 mo | Aspirin/Partial recovery | Left hemiparesis, paresthesia | Thrombocytosis, heterozygous for factor V Leiden mutation, family history of TIA, disease flare | Right MCA |
| Fukuhara et al. [42] | 18/M UC | 5 y | None/No sequel | Left hemiparesis | | Right pons |
| Gormally et al. [43] | 14/M CD | At disease onset | None/Partial recovery | Left hemiplegia, headache, seizure | Thrombocytosis | Right MCA |
| Keene et al. [20] | 13/F UC | At disease onset | None/No sequel | Seizure | Disease flare | Right cerebellar hemisphere |
| Lloyd-Still and Tomasi [44] | 5/M UC | At disease onset | None/Partial recovery, epilepsy developed 10 years later | Right hemiparesis, seizure | Disease flare | Left MCA |
| Mayeux and Fahn [29] | 17/M UC | Unknown | No*/Slow recovery | Sudden left loss of vision with signs of central retinal artery occlusion, seizure | Disease flare | Undetermined |
| Nelson et al. [45] | 18/M UC | Unknown | No/No sequel | Seizures, coma | Disease flare | Undetermined |
| Salloum et al. [46] | 15/F UC | 8 mo | Aspirin/No sequel | Left hemiparesis, right mouth angle deviation | None | Right MCA |
| Schneiderman et al. [47] | 12/F UC | 1 y | None/Death | Headache, seizure, hemianopia | Disease flare | Distal basilar artery |
| Standridge and de los Reyes [2] | 17/F IBD/U | At disease onset | Aspirin/No sequel | Severe headache, left-sided hemiparesis and hemiparesis, and right facial paresis | Disease flare, factor V Leiden heterozygote mutation, thrombocytosis | Left posterior parietal and right pontine/midbrain regions |
| Tomomasa et al. [48] | 1/F UC | Unknown | None/No improvement | Right hemiplegia, altered consciousness, seizures | Thrombocytosis, disease flare | Left MCA |
| Yassinger et al. [49] | 15/F IBD/U | Unknown | None/No sequel | Seizure, left hemiparesis | Disease flare | Undetermined |

*No refers to no administration of anticoagulants.

| IBD: inflammatory bowel disease, CD: Crohn's disease, UC: ulcerative colitis, IBD/U: inflammatory bowel disease unclassified, MCA: middle cerebral artery, TIA: transient ischemic attack. 

---

# Table 3. Demographics of patients pediatric inflammatory bowel disease complicated by cerebral venous thrombosis (CVE)

| Demographic data | Frequency |
|------------------|-----------|
| Age (y)          | 12.48±4.13 |
| Sex              |           |
| Female           | 32 (50.81) |
| Male             | 30 (49.39) |
| IBD type         |           |
| UC               | 43 (70.49) |
| CD               | 13 (21.31) |
| Phase of IBD     |           |
| Active           | 54 (87.93) |
| Passive          | 8 (12.07)  |
| Active disease   |           |
| Active UC        | 37 (86.04) |
| Active CD        | 10 (76.92) |
| Time interval between onset of IBD and CVE (mean, wk) | 20.84 |
| Presence of neurological symptoms of CVE at disease onset | |
| Yes              | 11 (26.83) |
| No               | 30 (73.17) |

Values are presented as mean±standard deviation or number (%).

IBD: inflammatory bowel disease, CD: Crohn's disease, UC: ulcerative colitis.
In total, 43 of 50 patients with CVT and nine of 12 patients with CAI had documented information on the sites of thrombosis and infarction, respectively. A review of these case reports revealed that the common sites of CVT were the transverse (n=23, 53.48%), superior sagittal (n=20, 46.51%), and sigmoid (n=16, 37.20%) sinuses. The right middle cerebral artery (MCA) (n=3, 33.34%) and left MCA (n=2, 22.23%) were the predominant sites of CAI. The frequencies of CVT and CAI sites are presented in Tables 5 and 6.

**Thrombosis and infarction sites**

In total, 43 of 50 patients with CVT and nine of 12 patients with CAI had documented information on the sites of thrombosis and infarction, respectively. A review of these case reports revealed that the common sites of CVT were the transverse (n=23, 53.48%), superior sagittal (n=20, 46.51%), and sigmoid (n=16, 37.20%) sinuses. The right middle cerebral artery (MCA) (n=3, 33.34%) and left MCA (n=2, 22.23%) were the predominant sites of CAI. The frequencies of CVT and CAI sites are presented in Tables 5 and 6.

**Risk factors for venous and arterial thrombosis**

Risk factors for venous or arterial thrombosis were identified in 59 of 62 patients. The predominant risk factor for CVE in most reports was IBD flares (59.32%). Thrombocytosis

### Table 4. Clinical manifestations of cerebrovascular event in patients with pediatric inflammatory bowel disease

| Clinical manifestations       | Frequency |
|------------------------------|-----------|
| Total                        | 62        |
| UC                          | 33        |
| CD                           | 29        |
| Headache                     | 38 (67.85)|
| Vomiting                     | 8 (14.28) |
| Seizure                      | 23 (41.07)|
| Sensory or motor neuropathy  | 28 (49.84)|
| Hemiparesis                  | 13 (23.21)|
| Hemiplegia                   | 5 (8.92)  |
| Paresthesia                  | 5 (8.92)  |
| Facial neurologic deficit    | 5 (8.92)  |
| Dysarthria                   | 1 (1.78)  |
| Aphasia                      | 4 (7.14)  |
| Altered level of consciousness| 9 (16.02)|
| Somnolence                   | 2 (3.57)  |
| Stupor                       | 1 (1.78)  |
| Confusion                    | 5 (8.92)  |
| Coma                         | 1 (1.78)  |
| Syncope                      | 1 (1.78)  |
| Ophthalmological findings    | 12 (21.36)|
| Orbital pain                 | 2 (3.57)  |
| Photophobia                  | 2 (3.57)  |
| Blurred vision               | 3 (5.35)  |
| Hemianopia                   | 2 (3.57)  |
| Ptosis                       | 1 (1.78)  |
| Papilledema                  | 1 (1.78)  |
| Loss of vision               | 1 (1.78)  |

Values are presented as number (%).

CD: Crohn's disease, UC: ulcerative colitis.

### Table 5. Sites of cerebral venous thrombosis (CVT) in patients with pediatric inflammatory bowel disease

| Location of CVT (vessels or brain region) | Value (n=43) |
|------------------------------------------|--------------|
| Transverse sinus                         | 23 (53.48)   |
| Superior sagittal sinus                  | 20 (46.51)   |
| Sigmoid sinus                            | 16 (37.20)   |
| Lateral sinus                            | 4 (9.30)     |
| Cavernous sinus                          | 1 (2.32)     |
| Cortical vein                            | 8 (18.60)    |
| Jugular vein                             | 3 (6.97)     |
| Occipital lobe                           | 1 (2.32)     |
| Frontal lobe                             | 2 (4.65)     |
| Parietal lobe                            | 3 (6.97)     |
| Thalamus                                 | 4 (9.30)     |
| Caudate nucleus                          | 1 (2.32)     |
| Putamen nucleus                          | 1 (2.32)     |

Values are presented as number (%).
and anemia were the main risk factors in 27.11% and 16.94% patients, respectively. Different coagulation defects, including elevated factor VIII levels (n=2), antithrombin III deficiency (n=1), and protein S deficiency (n=3), were reported in 10.16% patients. Hereditary thrombogenic mutations, such as factor V Leiden gene mutation (n=3), methylenetetrahydrofolate reductase (MTHFR) gene mutation (n=3), and prothrombin gene mutation (n=3), were also detected in 13.55% patients.

Laboratory examinations results showed elevated levels of lipoprotein (a) in one patient, elevated homocysteine levels in one (1.69%) patient, and presence of anticardiolipin antibodies in two (3.39%) patients. A positive family history of thromboembolism (e.g., deep vein thrombosis or transient ischemic attack) was reported in two (3.39%) patients. Overall, 16.95% patients showed no potential risk factors for CVE. Moreover, 43.94% patients had more than one risk factor, whereas 38.98% patients had only one risk factor. The probable risk factors for CVE are summarized in Tables 7 and 8.

### Table 6. Sites of cerebral arterial infarction (CAI) in patients with pediatric inflammatory bowel disease

| Location of CAI (vessels or brain region) | Value (n=9) |
|-----------------------------------------|-------------|
| Right MCA                               | 3 (33.34)   |
| Left MCA                                | 2 (22.23)   |
| Right pons                              | 2 (22.23)   |
| Right cerebellar hemisphere             | 2 (22.23)   |
| Distal basilar artery                   | 1 (11.12)   |
| Left posterior parietal region          | 1 (11.12)   |
| Midbrain                                | 1 (11.12)   |

Values are presented as number (%).

MCA: middle cerebral artery.

### Table 7. Risk factors of thromboembolism in patients with pediatric inflammatory bowel disease

| Risk factors                          | Value (n=59) |
|---------------------------------------|--------------|
| Disease flare                         | 35 (59.32)   |
| Thrombocytosis                        | 16 (27.11)   |
| Anemia                                | 10 (16.94)   |
| Family history of DVT                 | 2 (3.39)     |
| Protein S deficiency                  | 3 (5.08)     |
| Factor V Leiden mutation              | 3 (5.08)     |
| MTHFR mutation                        | 3 (5.08)     |
| Prothrombin gene mutation             | 3 (5.08)     |
| Anticardiolipin ab                    | 2 (3.39)     |
| Elevated fVIII                        | 2 (3.39)     |
| Elevated lipoprotein (a)              | 1 (1.69)     |
| Elevated homocysteine                 | 1 (1.69)     |
| Anti-thrombin III deficiency          | 1 (1.69)     |
| None                                  | 10 (16.95)   |

Values are presented as number (%).

MTHFR: methylenetetrahydrofolate reductase, DVT: deep vein thrombosis, fVIII: factor VIII.

### Table 8. Frequency of risk factors of thromboembolism in patients with pediatric inflammatory bowel disease

| Number of risk factors in each patient | Frequency |
|----------------------------------------|-----------|
| No risk factor                         | 10 (16.95)|
| One risk factor                        | 23 (38.98)|
| More than one risk factor              | 26 (43.94)|

Values are presented as number (%).
Data on therapy and patient outcomes were available for 59 of 62 patients. They were divided into four groups. The first group included 26 (44.06%) patients who received monotherapy with either unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH). Among them, 23 patients recovered completely, two partially recovered, and one died despite anticoagulant therapy due to progression of infarcts into the left hippocampus, right internal capsule, right thalamus, and right medial temporal lobe, with increasing edema, mass effect, and midline shift. During therapy, an 18-year-old boy presented with heparin-induced thrombocytopenia type II, but recovered completely after switching to another anticoagulant (fondaparinux).

The second group included seven (11.86%) patients who received warfarin therapy after heparin administration. Six of seven children treated with LMWH or UFH, followed by warfarin, recovered completely. The third group included six (10.17%) patients who received aspirin monotherapy. Therapy resulted in complete recovery in three patients, partial recovery in two patients, and death in one patient. Finally, in the fourth group, 18 (30.51%) patients who did not receive anticoagulants, seven recovered completely, seven partially recovered, three died, and one showed no improvement.

The decision to avoid anticoagulants in some patients was based on the presence of hemorrhagic infarctions or cerebral hemorrhages on brain computed tomography/magnetic resonance imaging and potential risk of intestinal bleeding. Overall, 41 (69.49%) patients, who were mostly administered UFH or LMWH (56.09%), recovered completely; 12 (20.34%) patients recovered partially; and five (8.47%) patients died, three of whom received no anticoagulant therapy. The outcomes of anticoagulant therapy are shown in Fig. 1.

**DISCUSSION**

This study aimed to better describe the phenomenon of CVE in pediatric patients with IBD. We performed a wide search using several databases. This series of 62 cases of CVE in children with IBD provides an interesting basis for new research hypotheses. Most of our patients had UC (70.5%), were in the active phase of IBD at the time of CVE (87.93%), had a mean age of 12.48±4.13 years, and had a mean time interval between the onset of IBD and CVE of 20.84 weeks. The most frequent symptoms were headaches, sensory and...
motor neuropathies, and seizures. The common sites of CVT were the transverse, superior sagittal, and sigmoid sinuses. The right and left MCA were the predominant sites of CAI. The predominant risk factor for CVE was IBD flares.

IBD is a known risk factor for thromboembolism. In a study by Nguyen and Sam [50], the incidence of thromboembolism was four to 20 times higher in children with IBD in comparison to children without IBD. CVE are the most common type of thromboembolism in children with IBD [51]. Similar to our review, several studies have highlighted a higher incidence of CVE in patients with UC than in those with CD, which could be due to the role of microvascular thrombosis in the disease process of UC. In other studies on adults and children, the incidence of thromboembolism was similar in male and female patients with IBD, which is in line with our findings [50-52].

The precise mechanism underlying thromboembolism in IBD is unknown. Thrombosis in PIBD consists of systemic thromboembolism events and focal microthrombi in the vasculature of the inflamed intestine [53]. Different aspects of IBD may be associated with the development of thrombosis. Specific factors may predispose patients to thrombosis. An IBD flare or activity was the most common risk factor (59.32%). Generally, chronic diseases associated with inflammation are risk factors for thromboembolism [4,54], and IBD is a disease with the highest degree of inflammation [4,55]. Although disease activity is a very important risk factor, there are reports of thromboembolism, even in patients with inactive UC or after colectomy [56-58]. In our review, most cases were in the active phase of IBD at the time of CVE, which is in line with the findings of Lazzerini et al. [51]. In this review, thrombocytosis (27.11%) was highlighted as a significant risk factor for CVE. Platelet activation and aggregation, in addition to thrombocytosis, increases the risk of thromboembolism [59,60]. Overall, 16.94% children experienced anemia. Anemia was the most common risk factor in a study by Katsanos et al. [1] on adult patients with IBD. However, the role of anemia as an independent risk factor for thromboembolism is controversial [4]. Moreover, inherited hypercoagulation disorders were detected in 32% patients. The detection rate of protein S deficiency, factor V Leiden gene mutations, prothrombin gene mutations, and MTHFR mutations were the same (5.08%). The detection rate of factor V Leiden gene mutation was similar in the studies by Katsanos et al. (7.6%) and Jackson et al. (5%) [1,61]. It appears that patients with IBD and thrombotic events are more heterozygous for factor V Leiden mutation than patients with IBD but without thrombotic complications [62]. Bernstein et al. [63] reported that factor V Leiden heterozygosity increased the risk of thrombosis by five- to eight-folds. In addition, MTHFR mutation was detected in 5.08% children in the literature. However, there are insufficient data regarding the association between MTHFR mutations and the risk of venous thrombosis [64-66]. Similar to the findings of our study, a previous study showed that prothrombin G20210A gene mutation was not common in patients with IBD compared to that in the general population; nevertheless, it caused a five-fold increase in the risk of thromboembolism [2].

There are no approved guidelines for the management of CVE in patients with PIBD; therefore, prevention needs to be prioritized. However, some important questions need to be addressed. One of these questions is related to the important risk factors for CVE in patients with PIBD, especially in outpatient settings. In total, 26.83% patients had CVE at presentation, and factors related to hospitalization, such as indwelling catheter and immobilization, were not involved. Although the disease was in remission in some cases, CVE were reported (12.07%). In addition, 16.95% patients had no risk factors, suggesting that
primary prevention should be considered. Moreover, according to a study by Lazzerini et al. [51], the risk factors for thromboembolism should be investigated in all patients. Therefore, early diagnosis and proper management of PIBD must be prioritized. Mucosal healing, which is the new goal of therapy for PIBD, may be more important than clinical remission. Further research must be conducted to determine whether early diagnosis, clinical and mucosal remission, and screening of risk factors together can prevent outpatient thrombosis.

During hospitalization, some important preventive measures include correction of anemia and dehydration, changing the treatment protocol or adjusting medications to control disease activity, avoiding immobilization, hypertension control, diagnosis and treatment of infection, and correct use and care of indwelling catheters. However, there are no definite guidelines for medical therapy with anticoagulants for either prevention or treatment. According to the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the management of severe acute colitis, prophylaxis is recommended for children with only one risk factor for thromboembolism; LMWH is the drug of choice [67]. Our findings revealed that nearly 83% patients had a risk factor for CVE, while almost 49% of them had more than one risk factor. In the latest guidelines for the management of stroke in children, the indications for primary or secondary prevention (after the first attack) are not recognized [68]. The best way to decide on long-term prophylaxis with anticoagulants is to consult with a hematologist. According to the new American Heart Association guidelines, medical therapy with aspirin or heparin (LMWH or UFH) is recommended within the first 5–7 days of admission for children with CVE if there is no contraindication [68]. Although a sample of 62 patients is not sufficient to compare the efficacy of medications, as shown in Fig. 1, heparin or heparin+warfarin is the most effective therapy to achieve the best outcomes. However, the outcomes of conservative management are poor in children. In addition, aspirin may not be as effective as heparin for CVE in patients with PIBD. Considering the differences in the treatment protocols applied to the patients, we could not determine the optimal dose or duration of therapy.

**CONCLUSION**

To our knowledge, CVE are the most common type of thromboembolism events in patients with PIBD, resulting in life-threatening complications and even death. Healthcare providers should improve their knowledge and awareness regarding the diagnosis, risk factors, therapeutic agents, and preventive options for CVE to obtain better neurological outcomes and decreased mortality rates. Therefore, further research is needed to determine the best practices for CVE management in patients with PIBD.

**REFERENCES**

1. Katsanos AH, Katsanos KH, Kosmidou M, Giannopoulos S, Kyritsis AP, Tsianos EV. Cerebral sinus venous thrombosis in inflammatory bowel diseases. QJM 2013;106:40143.
2. Standridge S, de los Reyes E. Inflammatory bowel disease and cerebrovascular arterial and venous thromboembolic events in 4 pediatric patients: a case series and review of the literature. J Child Neurol 2008;23:59-66.
3. Awab A, Elahmadi B, Elmoussaoui R, Elhijri A, Aililou M, Azzouzi A. Cerebral venous thrombosis and inflammatory bowel disease: reflections on pathogenesis. Colorectal Dis 2012;14:1153-4.

4. Barclay AR, Keightley JM, Horrocks I, Garrick V, McGrogan P, Russell RK. Cerebral thromboembolic events in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2010;16:677-83.

5. Al-Malik H, Green MR. Cerebral venous thrombosis as a complication of Crohn disease: a case report. J Pediatr Gastroenterol Nutr 2001;32:209-41. Erratum in: J Pediatr Gastroenterol Nutr 2001;33:428.

6. Al Tahan A, Mageed SA, Al Momen A, Zaidan R, Daif A, Al Tahan F. Cerebral venous thrombosis as a complication of ulcerative colitis associated with protein-S deficiency: case report and review of literature. Saudi J Gastroenterol 1998;4:34-7.

7. Mahmoud Reza A, Firozeh H, Houman A, Mehri NS. Pseudotumor cerebri in a case of ulcerative colitis with sagittal sinus thrombosis. Iran J Pediatr 2013;23:109-12.

8. Rabeh RB, Othman AB, Bouyahya O, Mrad SM, Boukthir S. P331 Extraintestinal manifestations of pediatric inflammatory bowel disease: a tunisian single-center experience. Arch Dis Child 2019;104 Suppl 3:A290.

9. Ben Sassi S, Mizouni H, Nabli F, Kallel L, Kefi M, Bentali F. Cerebral venous thrombosis presenting with cerebellar ataxia and cortical blindness. J Stroke Cerebrovasc Dis 2010;19:507-9.

10. Bridger S, Evans N, Parker A, Cairns SR. Multiple cerebral venous thromboses in a child with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1997;25:533-6.

11. Cognat E, Crassard I, Denier C, Vaheidi K, Bousser MG. Cerebral venous thrombosis in inflammatory bowel diseases: eight cases and literature review. Int J Stroke 2011;6:487-92.

12. Conners LM, Ahad R, Janda PH, Mudasir Z. Cerebral venous sinus thrombosis in a patient with ulcerative colitis flare. Case Rep Neurol Med 2018;2018:5798983.

13. Calderon A, Wong JW, Becker LE. Multiple cerebral venous thromboses in a child with ulcerative colitis. Clin Pediatr (Philad) 1993;32:169-71.

14. DeFilippis EM, Barfield E, Leifer D, Steinlauf A, Bosworth BP, Scherl EI, et al. Cerebral venous thrombosis in inflammatory bowel disease. J Dig Dis 2015;16:104-8.

15. Diakou M, Kostadima V, Giannopoulos S, Zikou AK, Argyropoulou MI, Kyritsis AP. Cerebral venous thrombosis in an adolescent with ulcerative colitis. Brain Dev 2011;33:49-51.

16. Houissa F, Salem M, Bouzaidi S, Rejeb MB, Mekki H, Debbeche R, et al. Cerebral thrombosis in inflammatory bowel disease: a report of four cases. J Crohn's Colitis 2011;5:249-52.

17. Jibaly R, Kaddourah A. P-0010: venous sinus thrombosis in a child with ulcerative colitis. Inflamm Bowel Dis 2009;15 Suppl 2:S7.

18. Kao A, Dlugos D, Hunter JV, Mamula P, Thorarsen O. Anticoagulation therapy in cerebral sinovenous thrombosis and ulcerative colitis in children. J Child Neurol 2002;17:479-82.

19. Kalbag RM, Woolf AL. Radiology, prognosis, pathology and treatment. In: Kalbag RM, Woolf AL, eds. Cerebral venous thrombosis: with special reference to primary aseptic thrombosis. London: Oxford University Press, 1967:237-50.

20. Keene DL, Matzinger MA, Jacob PJ, Humphreys P. Cerebral vascular events associated with ulcerative colitis in children. Pediatr Neurol 2001;24:238-43.

21. Kim I, Min KH, Yeo M, Kim JS, Lee SH, Lee SS, et al. Unusual case of cerebral venous thrombosis in patient with Crohn's disease. Case Rep Neurol 2015;7:115-20.
22. Kupfer SS, Rubin DT. Inflammatory bowel disease and cerebral venous sinus thrombosis. Gastroenterol Hepatol (N Y) 2006;2:914-7.

23. Kutluk G, Haciözcanoglu NE, Horozoglu H, Ertem D, Yılmaz Y. Cerebral venous thrombosis associated with childhood ulcerative colitis. Turk Arch Pediatr 2013;48:160-5.

24. Liu Y, Ren D, Zhou Q, Gao L. Cerebral sinovenous thrombosis in a child with ulcerative colitis: A case report. Medicine (Baltimore) 2020;99:e18649.

25. Maciri A, La Spina P, Terranova ML, Longo M, Gallitto G, Scuderi G, et al. Ulcerative colitis complicated by dural sinu venous thrombosis. Int J Colorectal Dis 2002;17:64-2.

26. Markowitz RL, Ment LR, Gryboski JD. Cerebral thromboembolic disease in pediatric and adult inflammatory bowel disease: case report and review of the literature. J Pediatr Gastroenterol Nutr 1989;8:413-20.

27. Martín-Masot R, Ortiz Pérez P, Serrano Nieto J, Martínez León M, Pascual Martínez A, Blasco-Alonso J, et al. Central venous sinus thrombosis in a boy with acute severe ulcerative colitis. Front Pediatr 2019;7:19.

28. Marušić E, Ursic A, Despot R, Simunovic M, Doric ML, Zitko V. Cerebral venous thrombosis a rare complication of ulcerative colitis – case report. Eur J Paediatr Neurol 2019;21 Suppl 1:e27.

29. Mayeux R, Fahn S. Strokes and ulcerative colitis. Neurology 1978;28:571-4.

30. Patterson M, Castiglioni L, Sampson L. Chronic ulcerative colitis beginning in children and teenagers. A review of 43 patients. Am J Dig Dis 1971;16:289-97.

31. Philips MF, Bagley LJ, Sinson GP, Raps EC, Galetta SL, Zager EL, et al. Endovascular thrombolysis for symptomatic cerebral venous thrombosis. J Neurosurg 1999;90:65-71.

32. Prasad RS, Michaels LA, Roychowdhury S, Craig V, Sorrell A, Schonfeld S. Combined venous sinus angioplasty and low-dose thrombolytic therapy for treatment of hemorrhagic transverse sinus thrombosis in a pediatric patient. J Pediatr Hematol Oncol 2006;28:196-9.

33. Rivera-Suazo Y, Argüello Calderon I, Vázquez-Frias R. Cerebral venous sinus thrombosis in a pediatric patient with inflammatory bowel disease: a case report. Rev Gastroenterol Mex (Engl Ed) 2020;85:364-6.

34. Robison NJ, Dawlabani N, Lastra CR, Dhall G. Cerebral sinus thrombosis in a child with active ulcerative colitis and factor V Leiden. Pediatr Blood Cancer 2009;52:867-9.

35. Rohani P, Javadzadeh M, Khalili M, Zojaji R. Cerebral venous thrombosis in a child with inflammatory bowel disease. Iran J Child Neurol 2021;15:159-66.

36. Rosen I, Berkovitz D, Soudack M, Ben Barak A, Brik R. Cerebral vein thrombosis in a child with Crohn’s disease. Isr Med Assoc J 2007;9:620-4.

37. Rousseau B, Bélanger C, Lacoursière Y, Bergeron MG, Saab M, Poncelet P. [Ulcerative colitis and cerebral venous thrombosis]. Union Med Can 1975;104:414-7. French.

38. Selvito P, Poretti A, Huisman TA, Wagner MW. Cerebral sinovenous thrombosis in a child with Crohn’s disease, otitis media, and meningitis. Neuroradiol J 2015;28:274-7.

39. Shahid R. Case series of two patients presenting with cerebral venous sinus thrombosis in association with ulcerative colitis. JSMC Clin Case Rep 2019;4:4.

40. Thorsteinsson GS, Magnussson M, Hallberg LM, Wahlgren NG, Lindgren F, Malmborg P, et al. Cerebral venous thrombosis and heparin-induced thrombocytopenia in an 18-year old male with severe ulcerative colitis. World J Gastroenterol 2008;14:4576-9.
41. Zitomersky NL, Levine AE, Atkinson BJ, Harney KM, Verhave M, Bousvaros A, et al. Risk factors, morbidity, and treatment of thrombosis in children and young adults with active inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2013;57:343-7.

42. Fukuhara T, Tsuchida S, Kinugasa K, Ohmoto T. A case of pontine lacunar infarction with ulcerative colitis. Clin Neurol Neurosurg 1993;95:159-62.

43. Gormally SM, Bourke W, Kierse B, Monaghan H, McMenamin J, Drumm B. Isolated cerebral thromboembolism and Crohn disease. Eur J Pediatr 1995;154:815-8.

44. Lloyd-Still JD, Tomasi L. Neurovascular and thromboembolic complications of inflammatory bowel disease in childhood. J Pediatr Gastroenterol Nutr 1989;9:461-6.

45. Nelson J, Barron MM, Riggs JE, Gutmann L, Schochet SS Jr. Cerebral vasculitis and ulcerative colitis. Neurology 1986;36:719-21.

46. Salloum R, Alhalabi N, Almidani MA. A case of Syrian child with cerebral infarction as an extraintestinal manifestation of ulcerative colitis. Case Rep Gastrointest Med 2019;2019:5984094.

47. Schneiderman JH, Sharpe JA, Sutton DM. Cerebral and retinal vascular complications of inflammatory bowel disease. Ann Neurol 1979;5:331-7.

48. Tomomasa T, Itoh K, Matsui A, Kobayashi T, Suzuki N, Matsuyama S, et al. An infant with ulcerative colitis complicated by endocarditis and cerebral infarction. J Pediatr Gastroenterol Nutr 1993;17:323-5.

49. Yassinger S, Adelman R, Cantor D, Halsed CH, Bolt RJ. Association of inflammatory bowel disease and large vascular lesions. Gastroenterology 1976;71:844-6.

50. Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008;103:2272-80.

51. Lazzerini M, Bramuzzo M, Maschio M, Martelossi S, Ventura A. Thromboembolism in pediatric inflammatory bowel disease: systematic review. Inflamm Bowel Dis 2011;17:2174-83.

52. Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001;85:430-4.

53. Wakefield AJ, Sawyer AM, Dhillon AP, Pittilo RM, Rowles PM, Lewis AA, et al. Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction. Lancet 1989;334:1057-62.

54. Hommes DW, van Dullemen HM, Levi M, van der Ende A, Woody J, Tytgat GN, et al. Beneficial effect of treatment with a monoclonal anti-tumor necrosis factor-alpha antibody on markers of coagulation and fibrinolysis in patients with active Crohn's disease. Haemostasis 1997;27:269-77.

55. Brynsvold J, Nielsen OH, Ahnfelt-Rønne I, Bendzken K. Cytokines (immunoinflammatory hormones) and their natural regulation in inflammatory bowel disease (Crohn's disease and ulcerative colitis): a review. Dig Dis 1994;12:290-304.

56. Miehls W, Reinisch W, Valic E, Osterode W, Tillinger W, Feichtenschlager T, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 2004;53:542-8.

57. Solem CA, Loftus EV Jr, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004;99:9701.

58. Angelberger S, Miehls W, Novacek G. Colonic involvement does not predispose to thrombosis in IBD. Inflamm Bowel Dis 2009;15:316-7.
59. Talbot RW, Heppell J, Dozois RR, Beart RW Jr. Vascular complications of inflammatory bowel disease. Mayo Clin Proc 1986;61:140-5.

60. Webberley MJ, Hart MT, Melikian V. Thromboembolism in inflammatory bowel disease: role of platelets. Gut 1993;34:247-51.

61. Jackson LM, O’Gorman PI, O’Connell J, Cronin CC, Cotter KP, Shanahan F. Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. QJM 1997;90:183-8.

62. Liebman HA, Kashani N, Sutherland D, McGehee W, Kam AL. The factor V Leiden mutation increases the risk of venous thrombosis in patients with inflammatory bowel disease. Gastroenterology 1998;115:830-4.

63. Bernstein CN, Sargent M, Vos HL, Rosendaal FR. Mutations in clotting factors and inflammatory bowel disease. Am J Gastroenterol 2007;102:338-43.

64. Spiroski I, Kedev S, Antov S, Arsov T, Krshevka M, Dzhekova-Stojkova S, et al. Association of methylenetetrahydrofolate reductase (MTHFR-677 and MTHFR-1298) genetic polymorphisms with occlusive artery disease and deep venous thrombosis in Macedonians. Croat Med J 2008;49:39-49.

65. Marjot T, Yadav S, Hasan N, Bentley P, Sharma P. Genes associated with adult cerebral venous thrombosis. Stroke 2011;42:913-8.

66. Gemmati D, Serino ML, Trivellato C, Fiorini S, Scapoli GL. C677T substitution in the methylenetetrahydrofolate reductase gene as a risk factor for venous thrombosis and arterial disease in selected patients. Haematologica 1999;84:824-8.

67. Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi IM, Bronsky J, et al. Management of paediatric ulcerative colitis, part 2: acute severe colitis—an evidence-based consensus guideline from the European Crohn’s and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:292-310.

68. Ferriero DM, Fullerton HJ, Bernard TJ, Billinghurst L, Daniels SR, DeBaun MR, et al. Management of stroke in neonates and children: a scientific statement from the American Heart Association/American Stroke Association. Stroke 2019;50:e51-96.